Interleukin-17A: Potential mediator and therapeutic target in hypertension
Tejera Muñoz, Antonio
Marquez Exposito, Laura
Santos Sanchez, Laura
Rayego Mateos, Sandra
Navarro González, Juan F.
MetadataShow full item record
Interleukin-17A (IL-17A) is a proinflammatory cytokine produced by cells of the immunesystem, predominantly Th17 and lymphocytes. In this paper, we review the role of IL-17A in the pathogenesis of hypertension and in target organ damage. Preclinical studiesin mice have shown that systemic adminstration of IL-17A increases blood pressure, prob-ably by acting on multiple levels. Furthermore, IL-17A plasma concentrations are alreadyelevated in patients with mild or moderate hypertension. Many studies in hypertensive mice models have detected IL-17A-producing cells in target organs such as the heart, vesselsand kidneys. Patients with hypertensive nephrosclerosis show kidney infiltration by Th17lymphocytes and lymphocytes that express IL-17A. In addition, in experimental models ofhypertension, the blockade of IL-17A by genetic strategies or using neutralizing antibodies,disminished blood pressure, probablyby acting on the small mesenteric arteries as well as inthe regulation of tubule sodium transport. Moreover, IL-17A inhibition reduces end-organsdamage. As a whole, the data presented in this review suggest that IL-17A participates in theregulation of blood pressure and in the genesis and maintenance of arterial hypertension,and may constitute a therapeutic target of hypertension-related pathologies in the future.
Is part ofNefrologia, 2021, vol. 41, núm. 3, p. 244–257
European research projects
The following license files are associated with this item: